Samuel T. Wilkinson, MD
Advertisement
Articles by Samuel T. Wilkinson, MD
Experts present the results of a retrospective analysis of patients who received IV ketamine for TRD over a timeframe of up to 2 years.
What is the efficacy of ECT for the treatment of dementia?
Samuel T. Wilkinson, MD, discusses the risks and benefits, as well as the challenges of clinical implementation of esketamine, for treatment-resistant depression.
Advertisement
Latest Updated Articles
Electroconvulsive Therapy for the Treatment of Dementia SymptomsOctober 14th 2024
What Is the Deal With Esketamine?April 6th 2020
Advertisement
Advertisement
Trending on Psychiatric Times
1
Kratom Component in Clinical Trial for Opioid Use Disorder
2
NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder
3
Why Cultural Context Matters in Psychiatric Assessment
4
FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder
5